Newborn Screening for the Diagnosis and Treatment of Duchenne Muscular Dystrophy

Author:

Farrar Michelle A.12,Kariyawasam Didu12,Grattan Sarah12,Bayley Klair3,Davis Mark4,Holland Sandra12,Waddel Leigh B.567,Jones Kristi5,Lorentzos Michelle867,Ravine Anja9,Wotton Tiffany9,Wiley Veronica9,

Affiliation:

1. Department of Paediatric Neurology, Sydney Children’s Hospital Network, Sydney, NSW, Australia

2. Discipline of Paediatrics, School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, NSW, Australia

3. Harry Perkins Institute of Medical Research, The University of Western Australia, Nedlands, WA, Australia

4. Department of Diagnostic Genomics, PathWest Laboratory Medicine, QEII Medical Centre, Perth, WA, Australia

5. Discipline of Child and Adolescent Health, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia

6. Kids Neuroscience Centre, The Children’s Hospital at Westmead, Westmead, NSW, Australia

7. Discipline of Paediatrics, University of Sydney, Sydney, NSW, Australia

8. The T.Y. Nelson Department of Neurology and Neurosurgery, The Children’s Hospital at Westmead, Sydney, NSW, Australia

9. NSW Newborn Screening Programme, Children’s Hospital Westmead, Westmead, NSW, Australia

Abstract

A pilot newborn screening (NBS) program for Duchenne muscular dystrophy (DMD) study proposes to assess the feasibility of the screening procedure, temporal course of the various steps of screening, and the public acceptability of the program. This is particularly vital to ascertain as DMD is considered a ‘non-treatable’ disease and thus does not fit the traditional criteria for newborn screening. However, modern perspectives of NBS for DMD are changing and point to possible net benefits for children and their families undertaking NBS for DMD. The aim of this workshop was to establish pathways for the successful implementation and evaluation of a pilot NBS for DMD program in Australia. Consensus was reached as to the rationale for, potential benefits, risks, barriers and facilitators of screening, alongside the establishment of screening protocols and clinical referral pathways.

Publisher

IOS Press

Subject

Neurology (clinical),Neurology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3